STOCK MARKET BSE NSE

Govt committed to buying another 4.5 crore doses of Covishield vaccine from Serum Institute

According to the purchase order placed on Monday, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.

Published: 12th January 2021 11:16 AM  |   Last Updated: 12th January 2021 11:16 AM   |  A+A-

covidshield

First consignment of COVID-19 vaccination arrives at Delhi Airport in a special SpiceJet flight from Pune. (Photo | PTI)

By PTI

NEW DELHI: The government has committed to buy from the Serum Institute further 4.5 crore doses of Oxford COVID-19 vaccine, Covishield, at a price of Rs 200 per shot plus applicable taxes by April, in addition to a firm order given to the company for 1.1 crore doses.

Fights have started ferrying the vaccines to different cities from Pune from Tuesday morning.

According to the purchase order placed on Monday, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.

The HLL Lifecare Limited, a public sector undertaking, issued the supply orders on behalf of the Union Health Ministry on Monday.

ALSO READ | First COVID-19 vaccine consignment reaches Delhi from Pune

The first order of 1.1 crore doses of Covishield will be worth Rs 231 crore, while the total amount including the commitment for 4.5 crore doses will amount to an estimated Rs 1,176 crore at current rates, according to sources.

"It is further informed that there is a commitment to purchase further 450 lakh doses from Serum Institute of India Pvt Limited, a manufacturer  (through subsidiary Serum Institute of Life Sciences Pvt Limited) at Rs 200 per dose plus GST if applicable by April 2021," the letter of comfort signed by Prakash Kumar Singh, Additional Director, Government and Regulatory Affairs at Serum Institute of India (SII) and R S Manku, Vice President (Govt Business) stated.

"This is in continuation to the supply order dated January 11 for supply of 1.1 crore doses of Covishield vaccine as approved by DCGI vide permission dated January 3 for restricted use in emergency situation," it stated.

The government on Monday also placed an order to Bharat Biotech for 55 lakh doses of indigenously developed Covaxin costing Rs 162 crore. India had recently approved two vaccines, Oxford's Covishield manufactured by SII in the country and Bharat Biotech's Covaxin, for restricted emergency use.

The country will launch its COVID-19 vaccination drive from January 16 in what Prime Minister Narendra Modi has called the world's largest inoculation programme with priority to be given to nearly three crore healthcare and frontline workers.

According to the COVID-19 Vaccine Operational Guidelines, the shots will be offered first to an estimated one crore healthcare workers, and around two crore frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities based on evolving pandemic situation.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp